Ariadne Wealth Management LP Acquires 417 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Ariadne Wealth Management LP grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 53.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,190 shares of the medical equipment provider’s stock after purchasing an additional 417 shares during the quarter. Ariadne Wealth Management LP’s holdings in Intuitive Surgical were worth $638,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. AlphaCore Capital LLC raised its holdings in shares of Intuitive Surgical by 4.2% during the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider’s stock valued at $235,000 after purchasing an additional 18 shares in the last quarter. Second Line Capital LLC grew its holdings in Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider’s stock valued at $302,000 after purchasing an additional 19 shares during the last quarter. Colonial Trust Co SC raised its position in shares of Intuitive Surgical by 8.8% in the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider’s stock valued at $128,000 after purchasing an additional 20 shares during the period. Crown Wealth Group LLC raised its position in shares of Intuitive Surgical by 4.8% in the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider’s stock valued at $218,000 after purchasing an additional 20 shares during the period. Finally, FSM Wealth Advisors LLC lifted its stake in shares of Intuitive Surgical by 3.8% in the first quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider’s stock worth $270,000 after buying an additional 20 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president directly owned 907 shares of the company’s stock, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary S. Guthart sold 2,800 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $495.24, for a total transaction of $1,386,672.00. Following the completion of the sale, the insider owned 18,520 shares in the company, valued at $9,171,844.80. This represents a 13.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,881 shares of company stock worth $7,920,634 over the last three months. Company insiders own 0.70% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $471.85 on Tuesday. The company has a market capitalization of $169.15 billion, a price-to-earnings ratio of 65.81, a PEG ratio of 4.93 and a beta of 1.59. The company has a 50-day moving average of $514.89 and a 200-day moving average of $527.45. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The company had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the previous year, the business earned $1.78 earnings per share. The company’s quarterly revenue was up 21.4% on a year-over-year basis. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ISRG shares. Deutsche Bank Aktiengesellschaft lowered shares of Intuitive Surgical from a “hold” rating to a “sell” rating and lowered their target price for the company from $515.00 to $440.00 in a research note on Monday, June 9th. Barclays lowered their price target on Intuitive Surgical from $684.00 to $635.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. Wall Street Zen upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Wells Fargo & Company raised their target price on Intuitive Surgical from $559.00 to $599.00 and gave the company an “overweight” rating in a report on Wednesday, July 23rd. Finally, Robert W. Baird dropped their price target on Intuitive Surgical from $600.00 to $575.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 23rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $595.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.